No Data
No Data
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open labe
Express News | HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Buy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical Trials
Protagonist Therapeutics, Inc. Just Recorded A 173% EPS Beat: Here's What Analysts Are Forecasting Next
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Statutory revenue of US$255m and earnings o
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
Protagonist Therapeutics Price Target Raised to $45.00/Share From $42.00 by JMP Securities
Protagonist Therapeutics Price Target Raised to $45.00/Share From $42.00 by JMP Securities
No Data